Duchenne and Becker muscular dystrophy are related conditions involving dystrophin, a protein that helps protect muscle fibers. They can affect skeletal muscle and the heart. Duchenne generally begins earlier and progresses faster; Becker is more variable. A name alone does not describe an individual’s abilities or future care needs. [1]

In this guide: What brings someone to assessment? · How is the diagnosis investigated? · Why does the DMD result matter? · Why is care broader than walking ability? · What should relatives know? · How should I evaluate a treatment claim? · Useful tools and related reading

What brings someone to assessment?

Delayed motor development, progressive weakness, difficulty rising or climbing stairs, or an unexpectedly high creatine kinase (CK) result may prompt investigation. CK is a muscle-associated enzyme measured in blood; an elevated result needs interpretation and is not specific to one diagnosis. Clinical assessment and molecular testing belong together. [2]

For an appointment, describe change over time rather than collecting isolated internet symptom matches. Record when a skill was first achieved, whether it has become harder, what teachers or family members have observed, and any existing test results. A short timeline can make a consultation more useful without trying to assign the diagnosis yourself.

How is the diagnosis investigated?

  1. Clinical assessment: a neuromuscular team evaluates the pattern of weakness, development and relevant family history.
  2. Laboratory context: bring the actual CK and other reports, including units and dates.
  3. Genetic testing: establish whether a clinically significant DMD alteration is present and what types of alteration the test evaluated.
  4. Resolve mismatches: ask what happens if the molecular result does not explain the clinical findings.
  5. Plan follow-up: identify who communicates the result and coordinates care and family counseling.

EMQN guidance addresses DMD exon deletions/duplications, sequence variants and selected RNA investigations. A test for one alteration class does not automatically exclude all other classes. A variant of uncertain significance neither confirms nor excludes a dystrophinopathy. [3]

Care map linking movement, heart, breathing and whole-person support through a coordinated record.
Care map linking movement, heart, breathing and whole-person support through a coordinated record. Original educational schematic; see article for sources and limits.

Why does the DMD result matter?

DMD encodes dystrophin, part of a protein complex linking the muscle cell’s internal framework to its surroundings. Pathogenic variants can impair the amount or function of this protein. The companion DMD gene guide explains exon changes, reading-frame predictions and the limits of molecular inference. [4]

Illustrative report-reading example: a family receives a message saying “a deletion was found.” Before discussing what it means, obtain the full report: gene, deleted exons or coordinates, reference sequence, classification and laboratory conclusion. The single word deletion cannot identify a treatment option or predict an individual clinical course.

Why is care broader than walking ability?

Cardiac and respiratory assessment, bone health and orthopaedic care are central parts of Duchenne management. Follow-up should not depend solely on whether someone notices symptoms or can still walk. The published care considerations emphasize coordinated specialist care across these areas. [5]

Rehabilitation, nutrition, development, education and transition to adult services also deserve attention. Ask the team how these needs fit into a shared plan, rather than treating every referral as an unrelated task. [6]

  • Who is the named coordinator for the overall care plan?
  • When are the next heart and respiratory assessments?
  • What movement, rehabilitation and equipment advice is appropriate now?
  • What school or workplace support would improve participation?
  • What information should emergency or anesthesia teams receive?
  • Which new symptoms should trigger a call before the next routine visit?

What should relatives know?

Dystrophinopathies are X-linked. Females with a pathogenic DMD variant can have cardiac or skeletal muscle involvement and should not automatically be described as unaffected. Family assessment may be important even when no previous diagnosis is known. Counseling should use the confirmed variant and the family’s circumstances. [2]

Begin with a documented result, then ask which relatives would benefit from a discussion. Keep untested relatives separate from relatives with a confirmed negative result. The cascade testing guide explains how to turn one established finding into a clear family-testing question.

How should I evaluate a treatment claim?

Separate three questions: does an intervention change dystrophin expression, does it improve a meaningful clinical outcome, and what harms or burdens accompany it? Write down the study population, exact variant eligibility, comparator, follow-up and missing results. An increase in a laboratory marker is not automatically equivalent to a lasting improvement in daily function.

For any proposed therapy, ask the treating team to check the current local authorization, eligibility and safety information. A historical article or trial announcement may no longer describe current use. This guide does not provide a drug-selection algorithm.

Useful tools and related reading

Read the DMD gene guide, what genetic tests can miss and how to read gene therapy trial results. Use the variant research assistant for an exact non-identifying query, the care finder for professional directories, and the research tools to locate original evidence.

Educational information, not an individual diagnosis or treatment plan. The current specialist-review status appears above. Illustrations are original educational examples, not patient records.